BioRestorative Therapies (OTCMKTS:BRTXQ) Shares Down 2.7% - Time to Sell?

Shares of BioRestorative Therapies, Inc. (OTCMKTS:BRTXQ - Get Free Report) traded down 2.7% during trading on Tuesday . The company traded as low as $1.0550 and last traded at $1.08. 26,495 shares were traded during mid-day trading, a decline of 100% from the average session volume of 62,169,492 shares. The stock had previously closed at $1.11.BioRestorative Therapies Stock Down 2.7%The firm's fifty day moving average is $1.40 and its two-hundred day moving average is $1.53. The firm has a market cap of $1.77 billion, a P/E ratio of -1.01 and a beta of 102.36. About BioRestorative Therapies (Get Free Report)BioRestorative Therapies, Inc develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders.Further ReadingFive stocks we like better than BioRestorative Therapies3 Grocery Stocks That Are Proving They Are Still Essential Consumers Got Coal, But Santa Dropped Off Big Gains for These 2 RetailersStock Ratings and Recommendations: Understanding Analyst Ratings10X Gains? These 3 Robotics Stocks Could Explode by 2035What is MarketRank™? How to Use itAnheuser-Busch Buys BeatBox to Win Over Younger DrinkersThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in BioRestorative Therapies Right Now?Before you consider BioRestorative Therapies, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioRestorative Therapies wasn't on the list.While BioRestorative Therapies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here